Barcelona, Spain, March 5th, 2021: Ona Therapeutics, a company focused on the discovery and development of therapeutic biologics to treat metastatic cancer, announces today that it has appointed Dr. Mark Throsby as independent board member of its Board of Directors. Dr. Throsby is a proven senior executive with more than 20 years of experience in the pharma & biotech industry and has led multiple drug discovery programs from conception to…
https://accure.health/accure-therapeutics-enrols-first-patient-in-phase-ii-clinical-trial-on-acute-optic-neuritis-with-lead-candidate-act-01/
https://www.asebio.com/actualidad/noticias/asebio-une-las-principales-gestoras-especializadas-de-capital-riesgo-para
https://mybinxhealth.com/news/binx-health-enters-into-distribution-agreement-for-national-launch-of-the-fda-cleared-binx-io/
https://accure.health/accure-therapeutics-publishes-pivotal-preclinical-efficacy-study-in-epilepsy/
https://www.sanifit.com/sanifit-granted-orphan-drug-designation-by-the-fda-for-snf472-for-the-treatment-of-peripheral-arterial-disease-in-patients-with-end-stage-kidney-disease/
https://accure.health/webinars-on-neuroprotection-for-brain-diseases-program/
https://www.plantadoce.com/empresa/alta-life-sciences-engorda-en-el-ano-del-covid-19-el-fondo-de-altamar-invierte-veinte-millones.html
https://accure.health/accure-therapeutics-appoints-dr-rossella-medori-as-chief-medical-officer/
• The financing round is led by Alta Life Sciences Spain I FCR, a vehicle managed by Altamar Private Equity SGIIC. Existing investors including Institut Català de Finances (ICF) have also participated in the financing. • Inbiomotion is in advanced stage of development of a single gene-based test for predicting response to bisphosphonates in breast cancer adjuvant setting and prevent metastasis. • The capital increase is intended to complete regulatory…
